Saturday, February 25, 2023
6:00 AM – 8:00 AM CT (Breakfast will be provided.)
San Antonio, TX
Texas AB (4th floor)
Grand Hyatt San Antonio River Walk
Mariana C. Castells, MD, PhD
Director Drug Hypersensitivity and Desensitization Center
Director Mastocytosis Center
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Tracy I. George, MD
Professor of Pathology
University of Utah School of Medicine
President and Chief Scientific Officer
Salt Lake City, Utah
Patricia L. Lugar, MD, MS
Section Chief, Allergy and Immunology
Associate Professor of Medicine
Co-Director, Jeffrey Modell Research and Diagnostic Center
Director, Medication Desensitization Program
Duke University Hospital
Durham, North Carolina
Anne L. Maitland, MD, PhD
Allergy/Immunology Specialist, Metrodora Institute
Salt Lake City, Utah
Assistant Clinical Professor, Icahn School of Medicine
Department of Medicine Allergy & Clinical Immunology
New York, New York
Join us for this unique, interactive, multimedia session guided by expert faculty!
Don’t forget to bring your mobile device and headphones!*
CAN'T ATTEND IN PERSON? NO PROBLEM!
You can participate virtually by accessing the activity here: https://www.exchangecme.com/sm
The URL will be live 15 minutes prior to the program!
For this Interactive Showcase™ in nonadvanced systemic mastocytosis (SM), grab your mobile device and headphones for a unique journey through several engaging educational experiences. The first activity, designed as an expert-guided poster tour, will briefly review the pathophysiological drivers of SM and their implications. Subsequently, you will attend a live expert roundtable where faculty will discuss management approaches, including recent clinical trial data on emerging targeted therapies and real-world strategies for comprehensive treatment. During the final activity you will participate in interactive case studies, applying information acquired to real-time management decisions. You don’t want to miss this!
Clinical immunologists/allergists, dermatologists, gastroenterologists, hematologists, and other clinicians who manage patients with nonadvanced SM.
After completing this activity, the participant should be better able to:
- Discuss SM pathophysiology, including implications for potential clinical presentations and new targeted therapies
- Evaluate patients with nonadvanced SM to characterize symptoms, disease burdens, and results from ancillary testing
- Discuss recent clinical trial evidence for new targeted treatment options in nonadvanced SM
- Individualize ongoing therapeutic regimens for nonadvanced SM based on symptomatology, patient-reported outcomes, and shared clinical decision making
6:00–6:15 AM CT Registration
6:15–6:25 AM CT Preactivity Questionnaire
6:25–6:45 AM CT Multimedia Poster Gallery
6:45–7:40 AM CT Meet the Professors Discussion on Systemic Mastocytosis
7:40–7:55 AM CT Case-Based Decision Tree
7:55–8:00 AM CT Postactivity Questionnaire
Disclosures of Conflicts of Interest
Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integritas Communications does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at firstname.lastname@example.org.
This activity is provided by Integritas Communications.
This activity is supported by an educational grant from Blueprint Medicines Corporation.
This activity is endorsed by The Mast Cell Disease Society, Inc.
There is no fee to attend this Non-CME Educational Program.
This program is not certified for continuing education credit. The content and opinions expressed are those of the sponsor and/or presenter(s) and are not necessarily those of the AAAAI.
**A limited number of loaner devices and earbuds will be available to participants as needed. Onsite staff will help guide everyone through the process of logging into the activity at registration.
Staying Vigilant for Immunocompromised Patients
Insights from a COVID-19 Expert Working Group
Answering the Call in Nonadvanced Systemic Mastocytosis: Targeted Approaches to Patient Management
Non-CME Corporate Forum Sponsored By Blueprint Medicines